MDB Capital teams with Mayo Clinic to advance anti-senescence platform

MDB Capital Holdings announced a collaboration through a patent and know-how agreement with Mayo Clinic to develop a small molecule anti-senescence platform. This collaboration aims to advance research in longevity and age-related disease prevention. Senescent cells, which are dysfunctional cells that have permanently stopped dividing, have been implicated in the aging process and the development of chronic low-grade inflammation. This chronic inflammation has been linked to a variety of age-related diseases, including multiple fibrotic conditions that have limited treatment options and poor prognoses.Studies conducted at Mayo Clinic have shown the potential of the licensed molecule to target and eliminate senescent cells with a significant therapeutic window, reversing fibrosis across multiple conditions. The global longevity and anti-senescence therapy market is projected to reach nearly $45 billion by 2030